[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hyperglycaemia-diabetic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hyperglycaemia-diabetic":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,54,90,131,162],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":34,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100639290","new-taipei-city-888-digital-medical-ai-platform-for-prevention-and-care-of-the-three-highs-and-cardio-renal-vascular-diseases-100639290",false,"NCT07588256","New Taipei City 888 Digital Medical AI Platform for Prevention and Care of the Three Highs and Cardio-Renal-Vascular Diseases","New Taipei City 888 Digital Medical AI Platform for the Prevention and Treatment of the Three Highs (Hypertension, Hyperglycemia, Hyperlipidemia) and Cardio-Renal-Vascular Diseases: Validation and Implementation Through Large-Scale Cluster Randomized Clinical Trials: T-888-DIGICARE-DREAM","DIGICARE-DREAM","Inclusion Criteria:\n\nI.T-888-DIGICARE：\n\nEligible participants must meet the definition of hypertension and at least one of the following chronic (non-hypertensive) conditions:\n\n1. Hypertension\n\n   * With or without treatment, and meeting one of the following:\n   * Office blood pressure: two consecutive measurements \\>130\u002F80 mmHg\n   * Home blood pressure: weekly average (morning\u002Fevening) \\>130\u002F80 mmHg, or more than half of the weekly measurements exceeding this threshold\n2. Hyperlipidemia\n\n   * With or without treatment, and\n   * LDL-C \\>100 mg\u002FdL (or \\>70 mg\u002FdL in patients with diabetes or established ASCVD)\n3. Diabetes Mellitus\n\n   * With or without treatment, and\n   * HbA1c \\>6.5%\n4. Chronic Kidney Disease (CKD)\n\n   * Estimated glomerular filtration rate (eGFR) \\\u003C60 mL\u002Fmin\u002F1.73 m², and\n   * Urine albumin-to-creatinine ratio (UACR) \\>30 mg\u002Fg\n5. Atherosclerotic Cardiovascular Disease (ASCVD):\n\n   * Including coronary artery disease, cerebrovascular disease, peripheral arterial disease, or aortic pathology\n\nII. DREAM-G:\n\n1. Hypertension\n\n   * With or without treatment, and meeting one of the following:\n   * Office blood pressure: two consecutive measurements \\>130\u002F80 mmHg\n   * Home blood pressure: weekly average (morning\u002Fevening) \\>130\u002F80 mmHg, or more than half of weekly measurements exceeding this threshold\n2. Hyperlipidemia\n\n   * With or without treatment, and\n   * LDL-C \\>100 mg\u002FdL (or \\>70 mg\u002FdL in patients with diabetes or established ASCVD)\n3. Diabetes Mellitus\n\n   * With or without treatment, and\n   * HbA1c \\>6.5%\n4. Chronic Kidney Disease (CKD)\n\n   * Estimated glomerular filtration rate (eGFR) \\\u003C60 mL\u002Fmin\u002F1.73 m², and\n   * Measurable urinary microalbumin-to-creatinine ratio\n5. Atherosclerotic Cardiovascular Disease (ASCVD):\n\n   • Including coronary artery disease, cerebrovascular disease, peripheral arterial disease, or aortic pathology\n\n   Participants must meet at least one of the above chronic disease conditions and:\n6. Untreated Hypertension:\n\n   * Morning home blood pressure (HBP) \\>130\u002F80 mmHg: weekly average (≥4 days) \\>130\u002F80 mmHg,\n   * Or more than half of morning HBP measurements (≥4 days per week) \\>130\u002F80 mmHg\n7. Treated Hypertension:\n\n   * Morning home blood pressure \\>130\u002F80 mmHg: weekly average (≥4 days) \\>130\u002F80 mmHg,\n   * Or more than half of morning HBP measurements (≥4 days per week) \\>130\u002F80 mmHg\n   * Average home blood pressure ≤130\u002F80 mmHg (used to determine treatment strategy)\n\nExclusion Criteria:\n\nI. T-888-DIGICARE\n\n1. Symptomatic heart failure (New York Heart Association functional class II-IV)\n2. End-stage renal disease requiring long-term dialysis\n3. Pregnant women or those planning pregnancy\n\nII. DREAM-G:\n\n1. Life expectancy \\\u003C1 year\n2. End-stage renal disease (ESRD) requiring regular renal replacement therapy, including dialysis, kidney transplantation, or palliative care\n3. Severe liver cirrhosis\n4. Malignancy under active treatment","ALL",{"count":19,"type":20},4162,"ESTIMATED","INTERVENTIONAL",[23],"NA","Non-communicable diseases (NCDs), or chronic diseases, are a major public health burden globally and in Taiwan, and control of the \"three highs\" (hypertension, dyslipidemia, and hyperglycemia) is a national priority. Nearly half of the 10 leading causes of death in Taiwan are directly or indirectly related to atherosclerotic cardiovascular disease (ASCVD), for which hypertension, dyslipidemia, and abnormal blood glucose are the major risk factors. National health insurance data indicate that over 70% of middle-aged and older adults have at least one of these chronic conditions. Early stages are often asymptomatic, and inadequate control may lead to complications of cardiovascular disease, stroke, renal vascular disease, and retinopathy, causing irreversible organ damage and death.\n\nFor blood pressure, large clinical trials such as SPRINT and STEP have shown that targeting systolic blood pressure below 130 mmHg significantly reduces ASCVD events. For LDL cholesterol, \"the lower, the better\" applies, with guideline-recommended LDL-C targets determined by baseline ASCVD risk, with levels below 55 mg\u002FdL for very high-risk patients. For diabetes, treatment goals generally include fasting plasma glucose below 130 mg\u002FdL and glycated hemoglobin (HbA1c) below 7%.\n\nAlthough antihypertensive therapy has been proven effective in preventing cardiovascular disease and chronic kidney disease attributable to hypertension, fewer than one-third of patients receiving antihypertensive medications achieve current guideline-recommended blood pressure targets. No randomized clinical trial to date has used home blood pressure as the primary therapeutic reference. Moreover, long-term evidence is lacking regarding the organ-protective effects of strategies targeting morning hypertension and of bedtime dosing regimens. Although the TIME study is currently the largest and longest-followed trial addressing dosing time, its bedtime-dosing arm was not specifically targeted to patients with morning hypertension. Therefore, we propose a clinical trial to investigate management strategies for morning hypertension. Aligned with the 2022 Taiwan Hypertension Guidelines, we will employ the \"722 protocol\" for home blood pressure monitoring and enroll patients with morning home blood pressure ≥130\u002F80 mmHg to compare selective nocturnal administration of antihypertensive agents versus exclusive morning dosing, assessing differences in morning home blood pressure control rates, end-organ damage, and atherosclerotic cardiovascular disease (ASCVD) events.\n\nThis project will implement two large-scale cluster-randomized clinical trials within the New Taipei City healthcare network. The first trial (T-888-DIGICARE) will evaluate whether a mobile digital health platform augmented with interactive digital modules can more effectively achieve the \"888\" targets for prevention and treatment of the Three Highs (Hypertension, Hyperglycemia, Hyperlipidemia). The second trial (DREAM-G) will use the same mobile health delivery model to investigate whether the timing of antihypertensive medication administration (nocturnal versus morning dosing) differentially affects patients with poor morning home blood pressure control. Beyond generating rigorous evidence through a novel clinical approach, this program is expected to have substantial global clinical impact and to showcase Taiwan's healthcare capabilities internationally. Operational challenges encountered and solutions developed during the trials will also provide critical feasibility data for the concurrent real-world implementation registry (T-888-DIGICARE-Registry). The registry will run in parallel with the cluster trials and will enroll individuals who decline trial participation at baseline as well as participants after trial completion, thereby serving as a continuity and real-world evidence platform.",[26,27,28,29,30,31,32,33],"Microalbuminuria","Microalbuminuria \u002FCreatinine Ratios ACR","Cardiovascular Disease Risk Factor","Cardiovascular Disease Prevention","Digital Medicine","Hypertension","Hyperglycaemia (Diabetic)","Hyperlipidemia",[35,36,37,38,39,40],"digital medicine","hypertension","home blood pressure monitoring","dyslipidemia","microalbuminuria","diabetes","RECRUITING","2026-05-11",{"date":44,"type":45},"2026-05-14","ACTUAL",{"date":47,"type":45},"2026-02-05",{"date":49,"type":20},"2029-02-05",{"name":51,"class":52},"New Taipei City Medical Association","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":17,"minAge":62,"maxAge":4,"enrollmentInfo":63,"targetDuration":65,"studyType":66,"phases":4,"briefSummary":67,"conditions":68,"keywords":72,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":53},"100631592","validation-of-remote-photoplethysmography-for-non-invasive-estimation-of-blood-glucose-and-hba1c-100631592","NCT07502690","Validation of Remote Photoplethysmography for Non-Invasive Estimation of Blood Glucose and HbA1c","Validation of Remote Photoplethysmography for Non-Invasive Estimation of Blood Glucose and HbA1c in a Community-Based Population in Jakarta","Inclusion Criteria:\n\n1. Adults aged ≥18 years\n2. Willing to participate and provide informed consent\n3. Able to undergo facial scan and blood examination\n4. Stable clinical condition\n\nExclusion Criteria:\n\n1. Facial conditions interfering with rPPG signal (e.g., wounds, deformities)\n2. Use of facial coverings obstructing camera detection\n3. Inability to remain still during facial scan\n4. Incomplete data or withdrawal from study",true,"18 Years",{"count":64,"type":20},300,"1 Day","OBSERVATIONAL","The goal of this observational study is to evaluate whether a non-invasive facial scan technology using remote photoplethysmography (rPPG) can accurately estimate blood glucose and HbA1c levels in adults living in the community in Jakarta. The study focuses on adults aged 18 years and older, including individuals with or without diabetes.\n\nThe main questions it aims to answer are:\n\n1. Can rPPG-based facial scan estimates of blood glucose and HbA1c match results from standard laboratory blood tests?\n2. How well can rPPG identify individuals with high blood sugar or diabetes risk based on established clinical cut-off values?\n\nResearchers will compare results from the rPPG facial scan with standard laboratory measurements of fasting blood glucose and HbA1c to determine how accurate and reliable the technology is for screening purposes.\n\nParticipants will:\n\n1. Provide basic information such as age, sex, and medical history\n2. Undergo a non-invasive facial scan using a smartphone-based system\n3. Have a blood sample taken to measure fasting blood glucose and HbA1c\n4. Complete all assessments during a single study visit\n\nThis study aims to determine whether rPPG can serve as a simple, non-invasive, and accessible tool for early detection and monitoring of diabetes in community settings.",[69,32,70,71],"Diabetes Mellitus","Hyperglycaemia (Non Diabetic)","Hypoglycaemia",[73,74,75,76,77,78,79],"remote photoplethysmography","rppg","blood glucose","HbA1c","diabetes mellitus","non-invasive monitoring","digital health screening","NOT_YET_RECRUITING","2026-04-15",{"date":83,"type":45},"2026-04-20",{"date":85,"type":20},"2026-03-23",{"date":87,"type":20},"2026-12-30",{"name":89,"class":52},"Tarumanagara University",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":62,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":21,"phases":99,"briefSummary":102,"conditions":103,"keywords":107,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":53},"100605835","phase-1-phase-1-trial-of-arginine-hydrochloride-for-the-management-of-diabetic-ketoacidosis-in-type-2-diabetes-100605835","NCT07167693","Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes","Phase 1 Randomized Clinical Trial of Arginine Hydrochloride Administration to Reduce Duration of Diabetic Ketoacidosis in Patients With Type 2 Diabetes","Inclusion Criteria:\n\n* Age \\>17 years.\n* Unscheduled presentation to a participating emergency department with hyperglycemia (serum glucose \\>250 mg\u002FdL) and significant ketonemia consistent with DKA, defined as laboratory serum\u002Fplasma β-hydroxybutyrate (BHB) \\>20 mg\u002FdL (≈≥1.9 mmol\u002FL).\n\nNote: point-of-care capillary BHB ≥1.5 mmol\u002FL and\u002For breath acetone ≥0.01% may be used for screening while confirmatory labs are pending; if confirmatory BHB ≤20 mg\u002FdL, the participant is a screen failure.\n\n* Clinical phenotype consistent with ketosis-prone type 2 diabetes (no known prior diagnosis of type 1 diabetes).\n* Able to provide written informed consent and comply with study procedures in the ED.\n\nExclusion Criteria:\n\n* Current renal replacement therapy for chronic kidney disease (hemodialysis or peritoneal dialysis).\n* Known history of type 1 diabetes mellitus or known GAD65 autoantibody positivity.\n* Diagnosed cirrhosis\u002Fadvanced chronic liver disease.\n* Pregnancy (known pregnancy or positive test at screening).\n* Known allergy or hypersensitivity to arginine or its components.\n* Features of at least moderate acute alcohol intoxication at screening, per treating team.",{"count":98,"type":20},60,[100,101],"PHASE1","PHASE2","Diabetic ketoacidosis (DKA) is increasingly recognized in adults with \"ketone-prone\" type 2 diabetes. In many of these patients, the pancreas can still make insulin but becomes temporarily \"stunned\" during severe, prolonged high blood sugar. Arginine is a naturally occurring amino acid that can trigger the pancreas to release its own insulin when glucose is high. It is FDA-approved for other uses and has been given intravenously for decades with a strong safety record. Whether a single arginine infusion given early during DKA can safely boost the body's insulin and speed recovery has not been tested.\n\nThis randomized, double-blind, placebo-controlled, phase 1\u002F2 trial will enroll 60 adults who present to one of four Detroit-area emergency departments with DKA consistent with ketone-prone type 2 diabetes (high glucose and significant ketones). Participants will receive standard DKA care ordered by their clinicians. In addition, under blinded conditions they will receive either arginine hydrochloride 30 grams (in 300 mL) or placebo (normal saline), infused intravenously over 30 minutes as early as feasible after DKA is recognized.\n\nThe main question is whether arginine increases endogenous (self-made) insulin soon after infusion. We will measure C-peptide (a marker released in equal amounts with insulin) and glucose at 10, 30, and 90 minutes after the start of the infusion and calculate the C-peptide\u002Fglucose ratio. Secondary measures include the rate of ketone (β-hydroxybutyrate) clearance and the total insulin dose required in the first 24 hours. Additional blood tests will examine arginine and related amino acids, and a small sample of platelets will be used to explore mitochondrial function. Safety will be closely monitored during and after the infusion, and participants will be contacted at 90 days to assess for any delayed problems.\n\nPotential risks include temporary flushing, nausea, or headache; the infusion can be stopped at any time if needed. Potential benefits include faster resolution of ketosis and reduced insulin needs, but benefits cannot be guaranteed for individual participants.",[104,105,106,32],"Diabetes (DM)","Diabetic Ketoacidosis","Ketosis Prone Diabetes",[108,109,110,111,112,113,114,115,116,117,118,119,120,121],"Arginine hydrochloride","Arginine","R-Gene 10","Insulin secretagogue","Endogenous insulin secretion","C-peptide","C-peptide to glucose ratio","Type 2 ketosis-prone diabetes (T2KPD)","Flatbush diabetes","Ketosis-prone diabetes (KPD)","Hyperglycemic crisis","Nitric oxide (NO)","Global arginine bioavailability ratio (GABR)","Mitochondrial function","2026-02-09",{"date":124,"type":45},"2026-02-12",{"date":126,"type":45},"2025-12-19",{"date":128,"type":20},"2027-12-31",{"name":130,"class":52},"David K Carroll",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":17,"minAge":62,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":21,"phases":141,"briefSummary":142,"conditions":143,"keywords":149,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":161},"100591776","evaluation-of-serum--and-oct-biomarkers-in-patients-with-dme-treated-with-anti-vegf-or-dexamethasone-implant-100591776","NCT06984822","Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant","Evaluation of Serum and Ocular Coherence Tomography Biomarkers in Patients With Diabetic Macular Edema Treated With Anti-VEGF or Dexamethasone Implant","BiomarkerOCT","Inclusion Criteria:\n\n* Type I or type II DM.\n* DME involving the center of the fovea with CFT more than 280 microns and the presence of intraretinal cysts.\n\nExclusion Criteria:\n\n* Prior history of any other macular disease.\n* Previous treatment with dexamethasone implants in the last six months for those in the anti-VEGF group.\n* Previous treatment with anti-VEGF in the last two months for those in the dexamethasone implant group.\n* Prior vitreoretinal surgery.\n* Previous laser treatment of the macula.\n* Previous panretinal photocoagulation.\n* Ocular surgery in the previous 3 months.",{"count":140,"type":20},150,[23],"This study aims to investigate the association between serum biomarkers and clinical response to anti-VEGF or dexamethasone implant by assessing OCT-biomarkers in patients with diabetic macular edema, DME, and to compare these with a group of naive patients (those not previously treated for DME).",[144,145,69,32,146,147,148],"Diabetic Macular Edema","Visual Impairment","Oxidative Stress","Vascular Endothelial Growth Factor","VEGF",[150],"optical coherence tomography","2025-11-17",{"date":153,"type":45},"2025-11-21",{"date":155,"type":45},"2025-08-01",{"date":157,"type":20},"2028-12-31",{"name":159,"class":160},"Vastra Gotaland Region","OTHER_GOV",2,{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":17,"minAge":62,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":21,"phases":173,"briefSummary":175,"conditions":176,"keywords":179,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":53},"100292453","phase-4-liraglutide-bolus-vs-glargine-bolus-therapy-in-overweightobese-type-2-diabetes-patients-liragood-100292453","NCT03087032","Liraglutide-bolus vs Glargine-bolus Therapy in Overweight\u002FObese Type 2 Diabetes Patients (LiraGooD)","Efficacy and Safety of Liraglutide-bolus (Liraglutide Plus Prandial Insulin) Versus Glargine-bolus Therapy in Overweight \u002F Obese Patients With Uncontrolled Type 2 Diabetes (LiraGooD)--A Multicenter Randomized Controlled Study","LiraGooD","Inclusion Criteria:\n\n* Age: 18 - 75 years old.\n* BMI must be greater than 24 and less than 45 kg\u002Fm2\n* Patients with type 2 diabetes who met the World Health Organization (who) diagnostic criteria (1999).\n* Newly diagnosed type 2 diabetic patients with HbA1c ≥ 9.0%；or patients with uncontrolled type 2 diabetes (HbA1c ≥ 7.5% ) who have received at least two types of oral hypoglycemic drugs (the dose of each drug needs to reach the second largest dose or more), or only insulin (excluding basal-bolus insulin therapy), or insulin with oral hypoglycemic drugs.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* History of pancreatic disease,\n* History of medullary thyroid carcinoma\n* Lipase level \\> 3 times above normal,\n* Creatinine clearance ≤ 30 mL\u002Fmin\u002F1.73m2,\n* Evidence in the last 6 months of significant heart disease or stroke, including myocardial infarction, unstable angina, coronary bypass and\u002For percutaneous transluminal coronary angioplasty, congestive heart failure (New York Heart Association Functional Classification III-IV), or severe ischemic heart disease.\n* Preparation for pregnancy or having been in pregnancy\n* Researchers believe that there are any factors that affect assessing subjects' participation in trial.\n* Patients unable to cooperate in clinical trials","75 Years",{"count":172,"type":20},164,[174],"PHASE4","The present 24-week, prospective, open-label, randomized, multicenter, parallel group trial is carried to investigate and evaluate the efficacy and safety of Liraglutide in combination with prandial insulin therapy vs insulin glargine in combination with prandial insulin therapy in overweight \u002F obese patients with uncontrolled type 2 diabetes.",[177,178,32],"Type 2 Diabetes Patients","Overweight and Obesity",[180,181,182],"Liraglutide","Insulin Glargine","Prandial Insulin","2025-01-09",{"date":185,"type":45},"2025-01-13",{"date":187,"type":45},"2019-01-10",{"date":189,"type":20},"2025-02-10",{"name":191,"class":52},"The First Affiliated Hospital of Xiamen University"]